Probiotix Health PLC - Wakefield, England-based life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions - Says it continues its scientific studies to support sales and marketing efforts with scientific presentations and publications and developing the product pipeline.

The company sees 2023 as a year of opportunity and continued growth and operational profitability, with a focus on commercialising products across more territories, particularly the US with larger partners, and increasing the proportion of final product to ingredient sales to partners and via its e-commerce platform. Looking ahead, Probiotix Health says it is confident and enthusiastic as a result of the large scale of market opportunity in probiotics, particularly outside the traditional gut health and health and wellbeing markets, where growth is slowing. "This is increasing interest in ProBiotix and its products from larger partners looking to sustain future growth", it adds.

Current stock price: EUR0.20

12-month change: down 99% from October 5

By Xindi Wei, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.